134 related articles for article (PubMed ID: 23322523)
21. Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer.
Piatek S; Panek G; Lewandowski Z; Bidzinski M; Piatek D; Kosinski P; Wielgos M
J Ovarian Res; 2020 Sep; 13(1):102. PubMed ID: 32878632
[TBL] [Abstract][Full Text] [Related]
22. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
[TBL] [Abstract][Full Text] [Related]
23. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels.
Prat A; Parera M; Adamo B; Peralta S; Perez-Benavente MA; Garcia A; Gil-Moreno A; Martinez-Palones JM; Baselga J; del Campo JM
Ann Oncol; 2009 Feb; 20(2):294-7. PubMed ID: 18820245
[TBL] [Abstract][Full Text] [Related]
24. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
[TBL] [Abstract][Full Text] [Related]
25. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
26. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
[TBL] [Abstract][Full Text] [Related]
27. Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report.
Skaznik-Wikiel ME; Sukumvanich P; Beriwal S; Zorn KK; Kelley JL; Richard SD; Krivak TC
Int J Gynecol Cancer; 2011 Aug; 21(6):1013-7. PubMed ID: 21792011
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
30. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer.
Colaković S; Lukiç V; Mitroviç L; Jeliç S; Susnjar S; Marinkoviç J
Int J Biol Markers; 2000; 15(2):147-52. PubMed ID: 10883888
[TBL] [Abstract][Full Text] [Related]
32. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
33. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
34. [CA 125 regression after two cycles of neoadjuvant chemotherapy as prognostic factor in patients with advanced ovarian cancer and primary peritoneal serous cancer who underwent interval surgical cytoreduction].
Gasowska-Bodnar A; Bodnar L; Wcisło GB; Jerzak MM; Szczylik C; Baranowski W
Ginekol Pol; 2008 Feb; 79(2):108-14. PubMed ID: 18510089
[TBL] [Abstract][Full Text] [Related]
35. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
36. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
[TBL] [Abstract][Full Text] [Related]
37. [Prognostic value of early normalization of CA 125 during chemotherapy in stages III and IV ovarian tumors].
Ferrero JM; Largillier R; Ramaioli A; Heudier P; Teissier E; Namer M
Bull Cancer; 1997 Jul; 84(7):722-8. PubMed ID: 9339198
[TBL] [Abstract][Full Text] [Related]
38. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients.
Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2011 Aug; 21(6):1040-7. PubMed ID: 21738039
[TBL] [Abstract][Full Text] [Related]
39. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
[TBL] [Abstract][Full Text] [Related]
40. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
